Viking Therapeutics Stock Climbs After Q4 Report: Details

Core Insights - Viking Therapeutics reported a quarterly loss of $1.38 per share, which was higher than the analyst estimate of a loss of 89 cents, indicating a significant miss in earnings expectations [2] - The increase in net loss was primarily attributed to a rise in research and development expenses, which totaled $153.5 million for the fourth quarter, compared to $31 million for the same period in 2024 [2] Group 1: Financial Performance - The increase in research and development expenses was mainly due to costs associated with clinical studies, stock-based compensation, and salaries and benefits, while there was a decrease in manufacturing expenses for drug candidates and preclinical studies [3] - The CEO of Viking, Brian Lian, highlighted that the past year was exceptional for the company, marked by rapid progress in their obesity portfolio [3] Group 2: Stock Performance - Viking Therapeutics stock experienced an increase of 8.58%, reaching a price of $31 during extended trading on Wednesday [4]